COMMUNIQUÉS West-GlobeNewswire

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, [...]
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone [...]
Autonomix Medical to Present at LSI USA ’26
11/03/2026
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior [...]
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a [...]
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
11/03/2026
SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
Trading by management and close relations of management
11/03/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
11/03/2026
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis treatment [...]
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
11/03/2026
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or [...]
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 16, 2026, as set out below. The report by the Board of Directors was [...]
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026
Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) , a molecular genetics diagnostic company [...]
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease First person has been dosed [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
Respiratory Medicine Publishes MATCH 2 Study Demonstrating Reliability of Real-Time Imaging Guidance in Robotic Bronchoscopy
11/03/2026
Study confirms 96.7% overall diagnostic yield due to precise lesion targeting using digital tomosynthesis and augmented fluoroscopy with CBCT verification SAN CARLOS, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Noah [...]
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11/03/2026
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from [...]
NurExone Announces Corporate Updates
11/03/2026
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ( [...]
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026
Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “ [...]
Community Care Cooperative (C3) Earns $10.2 Million in Shared Savings Through Medicare Shared Savings Program (MSSP) Track A for Performance Year 2024
11/03/2026
BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Community Care Cooperative (C3), the largest and most successful non-profit, FQHC-governed ACO in the country, announced today that it achieved $10.2 million in shared savings [...]

Pages